The institution’s principal investigator is Albert Cheung, department of anesthesiology, Hospital of the University of Pennsylvania.
Ischemic spastic paraplegia is a painful form of extreme spasticity and rigidity that causes permanent and untreatable loss of motor function and paralysis.
Richard Garr, Neuralstem’s president, said: “We are extremely pleased to be partnering with the University of Pennsylvania Hospital, and Dr Cheung’s team on this important milestone. They bring world-class experience and talent across the many disciplines that are required for moving into the clinic for our first human trial.”
Dr Cheung said: “We at Penn are deeply committed to finding a way to help these patients, and we are excited to be working with Neuralstem’s cutting-edge technology.”